INT73090

Context Info Confidence 0.49 First Reported 1997 Last Reported 1997 Negated 0 Speculated 0 Reported most in Abstract Documents 1 Total Number 1 Disease Relevance 0.41 Pain Relevance 0.08

extracellular region (FCGR3A) plasma membrane (FCGR3A)

FCGR3A (Homo sapiens)

Pain Link Frequency Relevance Heat Pain 1 81.76

Disease Link Frequency Relevance Heat Disease 2 97.38 Fever 1 82.32 Pain 1 81.76 Exanthema 1 77.76

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

A group of 15 patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural-killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fc gamma receptor III (CD16 antigen) and the Hodgkin's associated CD30 antigen.

Positive_regulation (directed) of CD16 Binding (associated) of associated with disease

1) Confidence 0.49 Published 1997 Journal Cancer Immunol. Immunother. Section Abstract Doc Link 9435869 Disease Relevance 0.41 Pain Relevance 0.08

General Comments

This test has worked.